Drug Profile
Meningococcal vaccine groups A B C Y W-135 conjugate - GSK
Alternative Names: GSK-3536819A; GSK3536819; MenABCWY (1st Gen); Meningococcal ABCWY Vaccine; rMenB + MenACWYLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer GSK
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Most Recent Events
- 26 Jul 2023 GSK announces intention to submit regulatory application for Meningococcal group ABCWY infections in European Union in the first half of 2024 (IM)
- 26 Jul 2023 GSK announces intention to submit regulatory application for Meningococcal group ABCWY infections in USA in the first half of 2024 (IM)
- 03 May 2023 GlaxoSmithKline completes a phase-III trial in Meningococcal group ABCY infections (In adolescents, Prevention, In adults) in Canada, Argentina, USA and Australia (IM) (NCT04707391) (EudraCT 2019-004982-42)